Abstract:Tumorigenesis is a complex and dynamic process involving cell-cell and cell-extracellular matrix (ECM) interactions that allow tumor cell growth, drug resistance and metastasis. This review provides an updated summary of the role played by the tumor microenvironment (TME) components and hypoxia in tumorigenesis, and highlight various ways through which tumor cells reprogram normal cells into phenotypes that are pro-tumorigenic, including cancer associated- fibroblasts, -macrophages and -endothelial cells. Tumor cells secrete numerous factors leading to the transformation of a previously anti-tumorigenic environment into a pro-tumorigenic environment. Once formed, solid tumors continue to interact with various stromal cells, including local and infiltrating fibroblasts, macrophages, mesenchymal stem cells, endothelial cells, pericytes, and secreted factors and the ECM within the tumor microenvironment (TME). The TME is key to tumorigenesis, drug response and treatment outcome. Importantly, stromal cells and secreted factors can initially be anti-tumorigenic, but over time promote tumorigenesis and induce therapy resistance. To counter hypoxia, increased angiogenesis leads to the formation of new vascular networks in order to actively promote and sustain tumor growth via the supply of oxygen and nutrients, whilst removing metabolic waste. Angiogenic vascular network formation aid in tumor cell metastatic dissemination. Successful tumor treatment and novel drug development require the identification and therapeutic targeting of pro-tumorigenic components of the TME including cancer-associated- fibroblasts (CAFs) and -macrophages (CAMs), hypoxia, blocking ECM-receptor interactions, in addition to the targeting of tumor cells. The reprogramming of stromal cells and the immune response to be anti-tumorigenic is key to therapeutic success. Lastly, this review highlights potential TME- and hypoxia-centered therapies under investigation.

Endothelial-to-Mesenchymal Transition in the Tumor Microenvironment: Roles of Transforming Growth Factor-β and Matrix Metalloproteins

Endothelial-to-mesenchymal transition in tumour progression and its potential roles in tumour therapy

Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells

The Role of Endothelial–mesenchymal Transition in Development and Pathological Process

Role of Endothelial Cells in the Regulation of Mechanical Microenvironment on Tumor Progression

TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering

Role of Tumor Microenvironment in Tumorigenesis

Unveiling the contribution of tumor-associated macrophages in driving epithelial-mesenchymal transition: a review of mechanisms and therapeutic Strategies

TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

Targeting Extracellular Matrix Interaction in Gastrointestinal Cancer: Immune Modulation, Metabolic Reprogramming, and Therapeutic Strategies

Tumour Microenvironment: a Non-Negligible Driver for Epithelial−mesenchymal Transition in Colorectal Cancer

The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis

Role of the Tumor Microenvironment in Tumor Progression and the Clinical Applications (Review).

Roles of genetic and microenvironmental factors in cancer epithelial-to-mesenchymal transition and therapeutic implication

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

Endothelin and the tumor microenvironment: a finger in every pie

Matrix Metalloproteinases in Tumorigenesis: an Evolving Paradigm

Epigenetic Regulation of Epithelial to Mesenchymal Transition in the Cancer Metastatic Cascade: Implications for Cancer Therapy

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited

Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution